These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 8027986

  • 1. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS, Hohman TC, Millen J.
    J Med Chem; 1994 Jun 24; 37(13):2043-58. PubMed ID: 8027986
    [Abstract] [Full Text] [Related]

  • 2. N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2.
    Malamas MS, Hohman TC.
    J Med Chem; 1994 Jun 24; 37(13):2059-70. PubMed ID: 8027987
    [Abstract] [Full Text] [Related]

  • 3. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
    Negoro T, Murata M, Ueda S, Fujitani B, Ono Y, Kuromiya A, Komiya M, Suzuki K, Matsumoto J.
    J Med Chem; 1998 Oct 08; 41(21):4118-29. PubMed ID: 9767647
    [Abstract] [Full Text] [Related]

  • 4. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Metabolism; 1979 Apr 08; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Adv Exp Med Biol; 1979 Apr 08; 119():347-56. PubMed ID: 115231
    [No Abstract] [Full Text] [Related]

  • 6. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D, Mirrlees DJ, Harrison HE, Earl DC.
    Metabolism; 1985 Apr 08; 34(4):336-44. PubMed ID: 3920474
    [Abstract] [Full Text] [Related]

  • 7. Spiro hydantoin aldose reductase inhibitors.
    Sarges R, Schnur RC, Belletire JL, Peterson MJ.
    J Med Chem; 1988 Jan 08; 31(1):230-43. PubMed ID: 3121857
    [Abstract] [Full Text] [Related]

  • 8. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor.
    Obrosova I, Faller A, Burgan J, Ostrow E, Williamson JR.
    Curr Eye Res; 1997 Jan 08; 16(1):34-43. PubMed ID: 9043821
    [Abstract] [Full Text] [Related]

  • 9. Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
    Wrobel J, Dietrich A, Woolson SA, Millen J, McCaleb M, Harrison MC, Hohman TC, Sredy J, Sullivan D.
    J Med Chem; 1992 Nov 27; 35(24):4613-27. PubMed ID: 1469692
    [Abstract] [Full Text] [Related]

  • 10. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats.
    Raccah D, Coste T, Cameron NE, Dufayet D, Vague P, Hohman TC.
    J Diabetes Complications; 1998 Nov 27; 12(3):154-62. PubMed ID: 9618071
    [Abstract] [Full Text] [Related]

  • 11. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D.
    Metabolism; 1985 Oct 27; 34(10):885-92. PubMed ID: 3930915
    [Abstract] [Full Text] [Related]

  • 12. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
    Horie S, Nagai H, Yuuki T, Narita Y, Tsuda Y, Nakajima T, Nakamura N.
    J Diabetes Complications; 1998 Oct 27; 12(3):163-9. PubMed ID: 9618072
    [Abstract] [Full Text] [Related]

  • 13. Potential aldose reductase inhibitors: 1,2,4-triazolidine-3,5-diones and 2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione .
    Hall IH, Izydore RA, Simlot R, Wong OT.
    Experientia; 1992 Apr 15; 48(4):383-6. PubMed ID: 1582496
    [Abstract] [Full Text] [Related]

  • 14. Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
    Wrobel J, Millen J, Sredy J, Dietrich A, Gorham BJ, Malamas M, Kelly JM, Bauman JG, Harrison MC, Jones LR.
    J Med Chem; 1991 Aug 15; 34(8):2504-20. PubMed ID: 1908522
    [Abstract] [Full Text] [Related]

  • 15. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
    Mylari BL, Armento SJ, Beebe DA, Conn EL, Coutcher JB, Dina MS, O'Gorman MT, Linhares MC, Martin WH, Oates PJ, Tess DA, Withbroe GJ, Zembrowski WJ.
    J Med Chem; 2005 Oct 06; 48(20):6326-39. PubMed ID: 16190759
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A, Diecke FP, Mistry K, Cruz E.
    Pharmacology; 1997 Feb 06; 54(2):76-83. PubMed ID: 9088040
    [Abstract] [Full Text] [Related]

  • 17. A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
    Karasova MJ, Prnova MS, Stefek M.
    Pharmazie; 2014 Oct 06; 69(10):747-51. PubMed ID: 25985564
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE, Cotter MA, Basso M, Hohman TC.
    Diabetologia; 1997 Mar 06; 40(3):271-81. PubMed ID: 9084964
    [Abstract] [Full Text] [Related]

  • 19. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor.
    Dvornik E, Simard-Duquesne N, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, Varma SD, Merola LO.
    Science; 1973 Dec 14; 182(4117):1146-8. PubMed ID: 4270794
    [Abstract] [Full Text] [Related]

  • 20. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.
    Sredy J, Sawicki DR, Notvest RR.
    J Diabet Complications; 1991 Dec 14; 5(1):42-7. PubMed ID: 1830318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.